RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.

"Conflict of interest Grzegorz S. Nowakowski: Consultancy and Membership on an entity’s Board of Directors or advisory committees: Celgene, MorphoSys, Genentech, Selvita, Debiopharm Group, Kite/Gilead; Research Funding: Celgene, NanoString Technologies, MorphoSys. Dok Hyun Yoon: No disclosure. Patrizia Mondello: No disclosure. Erel Joffe: Consultancy: AstraZeneca, Epizyme. Anthea Peters: Consultancy and Honoraria: AbbVie, Incyte. Isabelle Fleury: Conference and advisory role: AbbVie, AstraZeneca, BMS, Celgene, Janssen, Kite-Gilead, Merck, Novartis, Roche, Seattle Genetics. Richard Greil: Honoraria: Amgen, Sandoz, Sankyo, Sanofi, Gilead, Merck Sharp & Dohme, AstraZeneca, AbbVie, Takeda, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Novartis, Celgene; Other (travel, accommodations, expenses): Amgen, Sankyo, Sanofi, Gilead, Merck Sharp & Dohme, Janssen, AstraZeneca, AbbVie, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Novartis, Celgene; Research Funding: Amgen, Sandoz, Sankyo, Sanofi, Gilead, Merck Sharp & Dohme, AstraZeneca, AbbVie, Takeda, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Novartis, Celgene; Consultancy: Sankyo, Sanofi, Gilead, Merck Sharp & Dohme, Janssen, AstraZeneca, AbbVie, Takeda, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Novartis, Celgene; Membership on an entity’s Board of Directors or advisory committees: Sankyo, Sanofi, Gilead, Merck Sharp & Dohme, Janssen, AstraZeneca, AbbVie, Takeda, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Novartis, Celgene. Matthew Ku: Consultancy: Roche, Antegene, Genor Biopharma. Reinhard Marks: Membership on an entity’s Board of Directors or advisory committees: Kite/Gilead; Other (meeting attendance): AbbVie; Honoraria: Kite/Gilead; Consultancy: Merck. Kibum Kim: Research funding: AstraZeneca. Pier Luigi Zinzani: Consultancy: BeiGene, Bristol-Myers Squibb, Takeda, EUSA Pharma, ADC Therapeutics, Merck Sharp & Dohme, Celgene, Celltrion, Kyowa Kirin, Roche, Verastem, Sandoz, Novartis, Incyte, TG Therapeutics Inc, Servier, Janssen-Cilag, Gilead, ImmuneDesign, Sanofi; Membership on an entity’s Board of Directors or advisory committees: BeiGene, Bristol-Myers Squibb, Takeda, EUSA Pharma, ADC Therapeutics, Merck Sharp & Dohme, Celgene, Celltrion, Kyowa Kirin, Roche, Verastem, Sandoz, Novartis, Incyte, TG Therapeutics Inc, Servier, Janssen-Cilag, Gilead, ImmuneDesign, Portola, Sanofi, AbbVie; Speakers Bureau: BeiGene, Bristol-Myers Squibb, Takeda, EUSA Pharma, Merck Sharp & Dohme, Celgene, Celltrion, Kyowa Kirin, Roche, Verastem, Sandoz, Novartis, Incyte, TG Therapeutics Inc, Servier, Janssen-Cilag, Gilead, ImmuneDesign, Portola, AbbVie; Honoraria: Bristol Myers Squibb, Takeda, EUSA Pharma, ADC Therapeutics, Merck Sharp & Dohme, Kyowa Kirin, Roche, Verastem, Incyte, TG Therapeutics Inc, Servier, Janssen-Cilag, AbbVie; Research funding: Portola. Judith Trotman: Research funding: BeiGene, Celgene, Bristol-Myers Squibb, Roche, Janssen, PCYC Pharmacyclics. Lorenzo Sabatelli: Employee and equity holder of Incyte Biosciences International. Eva E. Waltl: Employee of MorphoSys AG. Mark Winderlich: Employee of MorphoSys AG with stock options, patents, and royalties. Andrea Sporchia: Employee of MorphoSys AG. Nuwan C. Kurukulasuriya: Employee and equity holder of MorphoSys AG with meetings/travel support provided by MorphoSys AG. Raul Cordoba: Research Funding: Pfizer; Membership on an entity’s Board of Directors or advisory committees: Kyowa-Kirin, Roche, AbbVie, ADC Therapeutics, Bristol-Myers Squibb, Incyte, Takeda, Janssen, Kite; Speakers Bureau: Roche, AbbVie, Bristol-Myers Squibb, Takeda, Janssen, Kite. Georg Hess: Honoraria: Roche, Janssen, Incyte, AbbVie, AstraZeneca, Genmab, Gilead, EUSA; Membership on an entity’s Board of Directors or advisory committees: Roche, Janssen, Incyte, AbbVie, AstraZeneca, Genmab, Gilead, EUSA; Research Funding: Roche, Janssen, Incyte, AbbVie, Gilead/Kite. Gilles Salles: Consultancy: Genmab, Epizyme, Roche/Genentech, Janssen, Ipsen, Novartis, Bristol-Myers Squibb/Celgene, BeiGene, AbbVie, Kite/Gilead, Incyte, Debiopharm, Loxo, Miltenyi, MorphoSys AG, Rapt, Regeneron, Takeda, Velosbio, Allogene; Membership on an entity’s Board of Directors or advisory committees: Genmab, Epizyme, Janssen, Roche/Genentech, Novartis, BeiGene, Kite/Gilead, Incyte, Debiopharm, Loxo, MorphoSys AG, Rapt, Takeda, Velosbio; Honoraria: Epizyme, Janssen, Bristol-Myers Squibb/Celgene, AbbVie, Bayer, MorphoSys AG, Regeneron."

"Funding statement This study was sponsored by MorphoSys AG."

"Clinical trial registration NCT04697160 (January 6, 2021)"